{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:45Z","timestamp":1786118925026,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,20]]},"abstract":"<jats:sec>\n                    <jats:title>\u00a0<\/jats:title>\n                    <jats:p>\n                      Evidence of a causal link between sclerostin-lowering interventions and ischemic stroke remains uncertain due to the limitations of previous observational studies and the post hoc analyses of randomized trials. Therefore, this study aims to investigate the causal effect of plasma sclerostin abundance on incident ischemic stroke and its subtypes. To do this, we conducted a drug-target Mendelian randomization analysis. First, we established a primary hypothesis holding that genetically perturbed plasma sclerostin levels are causally associated with any ischemic stroke (AIS). We then established exploratory hypotheses to test whether plasma sclerostin levels could affect the risk of subtypes of several types of ischemic stroke, in this case cardiometabolic stroke, large artery stroke (LAS), and small vessel stroke. For phenotypes that showed a statistically significant effect, we conducted Bayesian colocalization analyses to test for confounding by linkage disequilibrium. As a result, we identified a single\n                      <jats:italic toggle=\"yes\">cis<\/jats:italic>\n                      -acting genetic instrument perturbing plasma sclerostin levels. A significant effect of reduced sclerostin levels on increased odds for AIS was observed (odds ratio per 1-unit decrease in sclerostin levels: 1.32; 95% confidence interval: 1.03\u20131.68;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.027). Additionally, among the 3 subtypes of ischemic stroke, the odds for LAS were significantly affected by sclerostin levels under a Bonferroni-adjusted significance level (odds ratio: 2.71; 95% confidence interval: 1.31\u20135.61;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.007). No statistical evidence of confounding by linkage disequilibrium was observed with AIS (PP.H\n                      <jats:sub>3<\/jats:sub>\n                      \u2005=\u20054.13\u2005\u00d7\u200510\n                      <jats:sup>\u22123<\/jats:sup>\n                      ) or LAS (PP.H\n                      <jats:sub>3<\/jats:sub>\n                      \u2005=\u2005.0104). In conclusion, reduced plasma sclerostin levels could increase the risk of ischemic stroke, particularly LAS, suggesting the importance of monitoring cerebrovascular risk in patients receiving sclerostin-reducing therapies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048014","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T20:00:50Z","timestamp":1774036850000},"page":"e48014","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Effect of genetically proxied plasma sclerostin levels on the risk of ischemic stroke: A drug-target Mendelian randomization study"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1774-0588","authenticated-orcid":false,"given":"Woo Vin","family":"Lee","sequence":"first","affiliation":[{"name":"College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1836-1707","authenticated-orcid":false,"given":"Jung Mi","family":"Oh","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea"},{"name":"Natural Products Research Institute, Seoul National University, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4976-3343","authenticated-orcid":false,"given":"In-Wha","family":"Kim","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260422","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00198-022-06523-7","article-title":"Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders.","volume":"34","author":"Marini","year":"2023","journal-title":"Osteoporos Int"},{"key":"R2-20260422","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density.","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"R3-20260422","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.eprac.2023.06.011","article-title":"Romosozumab efficacy in postmenopausal women with no prior fracture who fulfill criteria for very high fracture risk.","volume":"29","author":"McClung","year":"2023","journal-title":"Endocrine Pract"},{"key":"R4-20260422","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis.","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"R5-20260422","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1210\/clinem\/dgae313","article-title":"Cardiovascular safety and romosozumab\u2014the plot thickens.","volume":"110","author":"Farr","year":"2025","journal-title":"J Clin Endocrinol Metabol"},{"key":"R6-20260422","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis.","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J Clin Endocrinol Metabol"},{"key":"R7-20260422","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11914-020-00652-w","article-title":"Romosozumab: a review of efficacy, safety, and cardiovascular risk.","volume":"19","author":"Fixen","year":"2021","journal-title":"Curr Osteoporos Rep"},{"key":"R8-20260422","doi-asserted-by":"crossref","first-page":"1064567","DOI":"10.3389\/fphar.2023.1064567","article-title":"An empirical comparison of the harmful effects for randomized controlled trials and non-randomized studies of interventions.","volume":"14","author":"Dai","year":"2023","journal-title":"Front Pharmacol"},{"key":"R9-20260422","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ije\/dyg070","article-title":"\u2018Mendelian randomization\u2019: can genetic epidemiology contribute to understanding environmental determinants of disease?","volume":"32","author":"Davey Smith","year":"2003","journal-title":"Int J Epidemiol"},{"key":"R10-20260422","doi-asserted-by":"crossref","first-page":"16","DOI":"10.12688\/wellcomeopenres.16544.1","article-title":"Mendelian randomization for studying the effects of perturbing drug targets.","volume":"6","author":"Gill","year":"2021","journal-title":"Wellcome Open Res"},{"key":"R11-20260422","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/0962280206077743","article-title":"Mendelian randomization as an instrumental variable approach to causal inference.","volume":"16","author":"Didelez","year":"2007","journal-title":"Stat Methods Med Res"},{"key":"R12-20260422","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jama.2021.18236","article-title":"Strengthening the reporting of observational studies in epidemiology using Mendelian randomization: the STROBE-MR statement.","volume":"326","author":"Skrivankova","year":"2021","journal-title":"JAMA"},{"key":"R13-20260422","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","article-title":"Plasma proteomic associations with genetics and health in the UK Biobank.","volume":"622","author":"Sun","year":"2023","journal-title":"Nature"},{"key":"R14-20260422","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41586-022-05165-3","article-title":"Stroke genetics informs drug discovery and risk prediction across ancestries.","volume":"611","author":"Mishra","year":"2022","journal-title":"Nature"},{"key":"R15-20260422","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41588-018-0058-3","article-title":"Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes.","volume":"50","author":"Malik","year":"2018","journal-title":"Nat Genet"},{"key":"R16-20260422","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/gepi.21998","article-title":"Bias due to participant overlap in two-sample Mendelian randomization.","volume":"40","author":"Burgess","year":"2016","journal-title":"Genet Epidemiol"},{"key":"R17-20260422","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature14878","article-title":"Whole-genome sequencing identifies EN1 as a determinant of bone density and fracture.","volume":"526","author":"Zheng","year":"2015","journal-title":"Nature"},{"key":"R18-20260422","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation.","volume":"526","author":"Consortium","year":"2015","journal-title":"Nature"},{"key":"R19-20260422","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43586-021-00092-5","article-title":"Mendelian randomization.","volume":"2","author":"Sanderson","year":"2022","journal-title":"Nat Revi Methods Primers"},{"key":"R20-20260422","doi-asserted-by":"crossref","first-page":"e34408","DOI":"10.7554\/eLife.34408","article-title":"The MR-Base platform supports systematic causal inference across the human phenome.","volume":"7","author":"Hemani","year":"2018","journal-title":"Elife"},{"key":"R21-20260422","doi-asserted-by":"crossref","first-page":"e1008720","DOI":"10.1371\/journal.pgen.1008720","article-title":"Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses.","volume":"16","author":"Wallace","year":"2020","journal-title":"PLoS Genet"},{"key":"R22-20260422","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1161\/ATVBAHA.122.317635","article-title":"Role of sclerostin in cardiovascular disease.","volume":"42","author":"Golledge","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R23-20260422","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.atherosclerosis.2016.08.003","article-title":"High serum levels of sclerostin and Dickkopf-1 are associated with acute ischaemic stroke.","volume":"253","author":"He","year":"2016","journal-title":"Atherosclerosis"},{"key":"R24-20260422","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.3390\/jcm10081660","article-title":"Cardiovascular safety profile of romosozumab: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system (FAERS).","volume":"10","author":"Vestergaard Kvist","year":"2021","journal-title":"J Clin Med"},{"key":"R25-20260422","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of a disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration.","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"R26-20260422","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/art.42538","article-title":"Lowering of circulating sclerostin may increase risk of atherosclerosis and its risk factors: evidence from a genome-wide association meta\u2010analysis followed by Mendelian randomization.","volume":"75","author":"Zheng","year":"2023","journal-title":"Arthr Rheumatol (Hoboken, N.J.)"},{"key":"R27-20260422","doi-asserted-by":"crossref","first-page":"9832","DOI":"10.1038\/s41467-024-53623-5","article-title":"Effect of genetically predicted sclerostin on cardiovascular biomarkers, risk factors, and disease outcomes.","volume":"15","author":"Alcalde-Herraiz","year":"2024","journal-title":"Nat Commun"},{"key":"R28-20260422","doi-asserted-by":"crossref","first-page":"186","DOI":"10.12688\/wellcomeopenres.15555.3","article-title":"Guidelines for performing Mendelian randomization investigations: update for summer 2023.","volume":"4","author":"Burgess","year":"2023","journal-title":"Wellcome Open Res"},{"key":"R29-20260422","doi-asserted-by":"crossref","first-page":"eabm5164","DOI":"10.1126\/sciadv.abm5164","article-title":"Proteomic profiling platforms head to head: leveraging genetics and clinical traits to compare aptamer-and antibody-based methods.","volume":"8","author":"Katz","year":"2022","journal-title":"Sci Adv"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:56:55Z","timestamp":1786035415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048014","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"2025-08-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}